Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Community Practice Connections™: Exploring the Modern Management of Pancreatic Cancer: Therapeutic Sequencing, Chemotherapy, and Novel Agents

Release Date: March 16, 2020
Expiration Date: March 16, 2021
Media: Internet - based

Activity Overview

Recent clinical trials have expanded potential treatment options in pancreatic cancer, a field that has had few options and limited advances for many years. This Community Practice Connection program will feature an online series of video interviews with experts in pancreatic cancer, in which they review and discuss key clinical trial data and ongoing research. With data emerging at a rapid pace, treating patients with pancreatic cancer will become more complex as new first-line and later-line treatment options become available. Clinicians that treat patients with pancreatic cancer find navigation of new treatment options challenging, including placing emerging data into clinical context for optimal treatment sequencing; appropriate application of neoadjuvant and adjuvant therapy options; and incorporation of radiotherapy with systemic treatments. In addition to new data guiding the use of chemotherapeutic options, personalized medicine is becoming a more probable reality for patients with pancreatic cancer. Identifying patients with BRCA mutations, mismatch repair deficiency, or NTRK fusions is already key to guiding treatment with PARP inhibitors, immune checkpoint inhibitors, or NTRK-targeted therapies, respectively. The expert panel will contextualize these recent updates to optimize the care of your patients with pancreatic cancer. The possible future treatment landscape for pancreatic cancer due to ongoing clinical trials and relevant preclinical research into the tumor microenvironment and immunological status, as well as targeted therapies in development, will be addressed.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video content until you finish the presentation.
  • At the end of the activity, “Educational Content Video” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational program is intended for medical oncologists, radiation oncologists, and surgical oncologists who treat patients with pancreatic cancer. Other attendees who have an interest in the treatment of pancreatic cancer, such as nurses, physician assistants, fellows, and residents, will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Assess the biological rationale and role of novel formulations of chemotherapeutic agents in expanding treatment options for pancreatic cancer.
  • Evaluate safety and efficacy data reported from recent clinical trials regarding emerging treatment options across lines of care in pancreatic cancer.
  • Integrate emerging data into the treatment paradigm for patients with pancreatic cancer.
  • Formulate a plan of care to monitor and mitigate adverse events associated with pancreatic cancer treatment options.

Faculty, Staff, and Planners’ Disclosures


Shubham Pant
Shubham Pant, MD
Associate Professor, Department of Investigational Cancer Therapeutics, Department of Gastrointestinal Medical Oncology
Associate Director, Department of Sheihk Ahmed Center for Early Phase Drug Development of Pancreatic Cancer Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Consultant: 4D Pharmacy Management Systems, Tyme Technologies Inc.

Matthew H.G. Katz
Matthew H.G. Katz, MD
Associate Professor, Department of Surgical Oncology, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: no relevant financial relationships with commercial interests.

George Kim
George Kim, MD
Chief, Gastrointestinal Cancer Program
Associate Professor of Medicine
George Washington University Cancer Center
Washington, DC

Disclosures: Consultant: Celgene, Ipsen, Merck; Speakers Bureau: Celgene, Ipsen.

Andrew H. Ko
Andrew H. Ko, MD, FASCO
Professor and Interim Chief, Division of Hematology/Oncology
The University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Paid directly to institution: AbGenomics, Apexigen, Astellas Pharma, Bristol-Myers Squibb, Celgene, Halozyme Therapeutics, Merck; Consultant: ERYTECH Pharma, Gritstone Oncology (1-time consultant), mugene (data monitoring committee).

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By